Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1999 Dec;81(6):496–499. doi: 10.1136/adc.81.6.496

Paediatric presentation of type 2 neurofibromatosis

D Evans 1, J Birch 1, R Ramsden 1
PMCID: PMC1718148  PMID: 10569966

Abstract

BACKGROUND—Neurofibromatosis type 2 (NF2) is a highly penetrant autosomal dominant condition predisposing affected individuals to schwannomas and meningiomas. The proportion of children presenting with meningioma or schwannoma who have NF2 is not well described, and neither is the mode of presentation in most children with the inherited disease.
AIMS—To determine the frequency of childhood meningioma and schwannoma cases caused by NF2 and the mode of presentation.
METHODS—The records of the Manchester Children's Tumour Registry from 1954 were searched for cases of meningioma and schwannoma. Paediatric presentation in a large UK series of NF2 was also studied.
RESULTS—18% (61/334) of patients with NF2 on the UK database presented in the paediatric age group (0-15 years), frequently with the symptoms of an isolated tumour. More than half had no family history to alert the clinician to their susceptibility. Three of 22 children presenting with a meningioma on the Manchester Children's Tumour Registry have gone on to develop classic features of NF2.
CONCLUSIONS—Clinicians should suspect NF2 in children presenting with meningioma, schwannoma, and skin features, such as neurofibromas/schwannomas, but fewer than 6 café au lait patches, who thus fall short of a diagnosis of neurofibromatosis type 1.


Full Text

The Full Text of this article is available as a PDF (76.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  2. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Strachan T., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992 Dec;29(12):847–852. doi: 10.1136/jmg.29.12.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans D. G., Maher E. R., Macleod R., Davies D. R., Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet. 1997 Sep;34(9):746–748. doi: 10.1136/jmg.34.9.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans D. G., Ramsden R., Huson S. M., Harris R., Lye R., King T. T. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993 May;107(5):401–406. doi: 10.1017/s002221510012328x. [DOI] [PubMed] [Google Scholar]
  6. Evans D. G., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998 Jun;35(6):450–455. doi: 10.1136/jmg.35.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. G., Wallace A. J., Wu C. L., Trueman L., Ramsden R. T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. doi: 10.1086/512074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381. doi: 10.1093/brain/111.6.1355. [DOI] [PubMed] [Google Scholar]
  9. Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Fünsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. doi: 10.1007/s004390050255. [DOI] [PubMed] [Google Scholar]
  10. Kluwe L., Mautner V. F. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998 Dec;7(13):2051–2055. doi: 10.1093/hmg/7.13.2051. [DOI] [PubMed] [Google Scholar]
  11. Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. doi: 10.1097/00006123-199605000-00004. [DOI] [PubMed] [Google Scholar]
  12. McGaughran J. M., Harris D. I., Donnai D., Teare D., MacLeod R., Westerbeek R., Kingston H., Super M., Harris R., Evans D. G. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999 Mar;36(3):197–203. [PMC free article] [PubMed] [Google Scholar]
  13. Miyamoto R. T., Campbell R. L., Fritsch M., Lochmueller G. Preservation of hearing in neurofibromatosis 2. Otolaryngol Head Neck Surg. 1990 Oct;103(4):619–624. doi: 10.1177/019459989010300416. [DOI] [PubMed] [Google Scholar]
  14. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  15. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  16. Rouleau G. A., Wertelecki W., Haines J. L., Hobbs W. J., Trofatter J. A., Seizinger B. R., Martuza R. L., Superneau D. W., Conneally P. M., Gusella J. F. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. doi: 10.1038/329246a0. [DOI] [PubMed] [Google Scholar]
  17. Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed] [Google Scholar]
  18. Seizinger B. R., Rouleau G. A., Ozelius L. J., Lane A. H., Faryniarz A. G., Chao M. V., Huson S., Korf B. R., Parry D. M., Pericak-Vance M. A. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987 Jun 5;49(5):589–594. doi: 10.1016/0092-8674(87)90534-4. [DOI] [PubMed] [Google Scholar]
  19. Slattery W. H., 3rd, Brackmann D. E., Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998 Sep;19(5):638–643. [PubMed] [Google Scholar]
  20. Wu C. L., Thakker N., Neary W., Black G., Lye R., Ramsden R. T., Read A. P., Evans D. G. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet. 1998 Dec;35(12):973–977. doi: 10.1136/jmg.35.12.973. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES